Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) has received several requests from Saudi Arabia, Kuwait, Iraq, and Yemen for the purchase of the antiviral Anviziram for treatment of the novel coronavirus (COVID-19), Rameda’s CEO Amr Morsy told Reuters.
The pharmaceuticals firm awaits the Egyptian Ministry of Health’s approval to export the antiviral drug, Morsy noted.
Earlier, Rameda announced that it has started manufacturing the antiviral Anviziram, which contains the active pharmaceutical ingredient Favipiravir, a generic form of the Japanese antiviral Avigan.
The medicine will be supplied to the Ministry of Health to be available at hospitals only. Negotiations are still underway to determine the medicine price, which is set to be released by the end of July.
Next week, Rameda will enter into discussions with the Egyptian authorities to explore the possibility of exporting the medicine to GCC in the coming period, the Morsy concluded.
